BioSpace News Archive

Akebia Therapeutics, Inc. granted four newly-hired employees options to purchase an aggregate of 21,300 shares of Akebia’s common stock

Bruker Corporation announced it will present at the following conferences

MAXIMUS announced that Bruce Caswell, President and CEO, will present at the Jefferies Global Healthcare Conference

Deciphera Pharmaceuticals, Inc. announced that it has commenced a proposed public offering of 3,750,000 in shares of its common stock.

Cellectis announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for UCART22.

The Agriculture Energy Coalition applauded a bipartisan group of eight members of the Senate Committee on Agriculture, Nutrition and Forestry who expressed their strong support for the farm bill energy title programs in a letter to committee chair Sen. Pat Roberts (R-KS) and ranking member Sen. Debbie Stabenow.

BERG, LLC presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting.

BIO’s latest report shows that the U.S. bioscience industry has reached record setting annual economic impact, venture capital investment and job growth numbers.

The U.S. Food and Drug Administration approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim)

Human Proof-of-Concept (PoC) Trial to Evaluate the Superiority of RK-01 Over Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control.